Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by inflammation and scarring of the bile ducts, which can lead to cirrhosis and hepatic decompensation. The study aimed to explore the potential value of computational radiomics, a field that extracts quantitative features from medical images, in predicting whether or not PSC patients had hepatic decompensation. We used an in-house developed deep learning model called the body composition model, which quantifies body composition from computed tomography (CT) into four compartments: subcutaneous adipose tissue (SAT), skeletal muscle (SKM), visceral adipose tissue (VAT), and intermuscular adipose tissue (IMAT). We extracted radiomics features from all four body composition compartments and used them to build a predictive model in the training cohort. The predictive model demonstrated good performance in validation cohorts for predicting hepatic decompensation, with an accuracy score of 0.97, a precision score of 1.0, and an area under the curve (AUC) score of 0.97. Computational radiomics using CT images shows promise in predicting hepatic decompensation in primary sclerosing cholangitis patients. Our model achieved high accuracy, but predicting future events remains challenging. Further research is needed to validate clinical utility and limitations.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11584029PMC
http://dx.doi.org/10.18632/oncotarget.28673DOI Listing

Publication Analysis

Top Keywords

hepatic decompensation
20
body composition
16
predicting hepatic
12
adipose tissue
12
composition model
8
decompensation primary
8
primary sclerosing
8
sclerosing cholangitis
8
computational radiomics
8
predictive model
8

Similar Publications

Background: The clinical course and outcomes of alcohol-associated hepatitis (AH) remain poorly understood. Major adverse liver outcomes (MALO) do not capture the added risk of return to drinking (RTD). We examined the natural history of AH and developed a composite endpoint using a contemporary observational cohort of AH.

View Article and Find Full Text PDF

Hepatic hydrothorax (HH) occurs in 4%-12% of patients with cirrhosis and rarely presents without accompanying evidence of clinically significant portal hypertension (CSPH). We report the case of a 65-year-old man with cirrhosis without prior decompensation, congestive heart failure, and recurrent right-sided pleural effusion. CSPH was not otherwise observed despite thorough laboratory, radiologic, and endoscopic evaluation.

View Article and Find Full Text PDF

Background & Aims: Conflicting evidence exists on hepatocellular carcinoma (HCC) risk in patients with chronic hepatitis B (CHB) receiving tenofovir entecavir. We assessed the impacts of the two drugs on the clinical trajectory of CHB at a population level.

Methods: We conducted a retrospective nationwide cohort study using data from Taiwan's National Health Insurance Research Database, including 55,885 patients with CHB who were treatment-naïve aged 30-75 years receiving tenofovir (n = 17,137) or entecavir (n = 38,748) monotherapy for ≥3 months between November 2009 and December 2020, and followed until December 2022.

View Article and Find Full Text PDF

Extrapulmonary tuberculosis (TB), particularly when it involves the central nervous system (CNS), remains a significant clinical challenge. Cerebral tuberculoma, though rare, can present with complex symptoms that overlap with other neurological conditions, making timely diagnosis difficult. The condition demands a multidisciplinary approach for accurate diagnosis and effective management, especially in patients with multiple comorbidities.

View Article and Find Full Text PDF